PubRank

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Clinical Trial ID NCT01454596

PubWeight™ 46.99‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01454596

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 74.55
2 The basic principles of chimeric antigen receptor design. Cancer Discov 2013 3.28
3 Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015 1.91
4 Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012 1.75
5 Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014 1.61
6 Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg 1958 1.49
7 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
8 CAR T cells for solid tumors: armed and ready to go? Cancer J 2014 1.29
9 EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2013 1.22
10 Combined modality therapy for intracranial tumors. Cancer 1975 1.14
11 Driving CAR T-cells forward. Nat Rev Clin Oncol 2016 1.09
12 An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines 2013 1.08
13 Immunotherapy advances for glioblastoma. Neuro Oncol 2014 1.07
14 Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 2012 1.03
15 Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res 2015 1.00
16 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. MAbs 2012 0.99
17 Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 2013 0.97
18 Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res 2016 0.95
19 Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res 2014 0.92
20 The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 2014 0.91
21 Adoptive cell therapies for glioblastoma. Front Oncol 2013 0.90
22 Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015 0.89
23 Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology 2015 0.88
24 Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy 2014 0.87
25 Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. J Immunother 2015 0.87
26 Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics 2016 0.86
27 Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int 2014 0.86
28 Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Rep Oncol Med 2015 0.85
29 Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) 2015 0.85
30 Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012 0.84
31 Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 2015 0.84
32 The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res 2015 0.84
33 Genetically engineered T cells for the treatment of cancer. J Intern Med 2013 0.83
34 Improving vaccine efficacy against malignant glioma. Oncoimmunology 2016 0.81
35 Immunotherapeutic advancements for glioblastoma. Front Oncol 2015 0.81
36 Immunotherapy for malignant glioma. Surg Neurol Int 2015 0.81
37 Are BiTEs the "missing link" in cancer therapy? Oncoimmunology 2015 0.81
38 Genetically modified T cells to target glioblastoma. Front Oncol 2013 0.80
39 Clinical trials in cellular immunotherapy for brain/CNS tumors. Expert Rev Neurother 2013 0.79
40 Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther 2016 0.79
41 Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. Ann Transl Med 2016 0.78
42 Emerging immunotherapies for glioblastoma. Expert Opin Emerg Drugs 2016 0.77
43 Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther 2016 0.77
44 Cellular immunotherapy for pediatric solid tumors. Cytotherapy 2014 0.77
45 New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci 2016 0.77
46 Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology 2016 0.76
47 Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol 2016 0.75
48 Neoantigen-based cancer immunotherapy. Ann Transl Med 2016 0.75
49 Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Onco Targets Ther 2016 0.75
50 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
51 Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery 2014 0.75
52 Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg 2014 0.75
Next 100